Received Jun 29, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | Unknown | — |
The patient coming back to receive the second dose of RabAvert six weeks after the first dose; Case reference number US-BN-2026-000552 is a spontaneous case initially received from nurse via Bavarian Nordic (reference number: CASE-2026-000175) on 02-Apr-2026 and concerns an adult patient of unknown gender and age. The patient's medical history and concomitant medication details were not provided. On an unknown date, the patient received the first dose of RabAvert along with its constituent parts prefilled syringe, needle for injection and needle for reconstitution (batch number: unknown), at an unknown dose, site or route of administration for pre-exposure prophylaxis. As reported, the patient coming back to receive the second dose of RabAvert six weeks after receiving the first dose (explicitly coded as 'incomplete course of vaccination'). At the time of the initial report, it is unknown if the patient experienced any adverse event due to RabAvert. No further information was provided.; Reporter's Comments: This case concerns about an adult patient of unknown gender and age. As reported, As reported, the patient come back to receive the second dose of RabAvert six weeks after receiving the first dose, for an indication of pre-exposure prophylaxis, which is considered as incomplete course of vaccination. Event incomplete course of vaccination is considered as listed per company convention. At the time of the initial report, it is unknown if the patient experienced any adverse event due to RabAvert. The patient's medical history and concomitant medication details were not provided. Incomplete course of vaccination is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious. For regulatory reporting purposes, this case is considered not related.; Sender's Comments: This case concerns about an adult patient of unknown gender and age. As reported, As reported, the patient come back to receive the second dose of RabAvert six weeks after receiving the first dose, for an indication of pre-exposure prophylaxis, which is considered as incomplete course of vaccination. Event incomplete course of vaccination is considered as listed per company convention. At the time of the initial report, it is unknown if the patient experienced any adverse event due to RabAvert. The patient's medical history and concomitant medication details were not provided. Incomplete course of vaccination is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious. For regulatory reporting purposes, this case is considered not related.
Comments: None.